These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 17127188)

  • 1. Gallstone disease: Primary and secondary prevention.
    Venneman NG; van Erpecum KJ
    Best Pract Res Clin Gastroenterol; 2006; 20(6):1063-73. PubMed ID: 17127188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Failure of cholecystokinin-octapeptide to prevent TPN-associated gallstone disease.
    Tsai S; Strouse PJ; Drongowski RA; Islam S; Teitelbaum DH
    J Pediatr Surg; 2005 Jan; 40(1):263-7. PubMed ID: 15868595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biliary microlithiasis in patients with idiopathic acute pancreatitis and unexplained biliary pain: response to therapy.
    Saraswat VA; Sharma BC; Agarwal DK; Kumar R; Negi TS; Tandon RK
    J Gastroenterol Hepatol; 2004 Oct; 19(10):1206-11. PubMed ID: 15377301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of biliary complications in bariatric surgery.
    Desbeaux A; Hec F; Andrieux S; Fayard A; Bresson R; Pruvot MH; Mulliez E
    J Visc Surg; 2010 Aug; 147(4):e217-20. PubMed ID: 20920904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery: study protocol for a randomized controlled trial (UPGRADE trial).
    Boerlage TCC; Haal S; Maurits de Brauw L; Acherman YIZ; Bruin S; van de Laar AWJM; Moes DE; van Wagensveld BA; de Vries CEE; van Veen R; Schouten R; Dijkgraaf MG; Fockens P; Gerdes VEA; Voermans RP
    BMC Gastroenterol; 2017 Dec; 17(1):164. PubMed ID: 29262795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term ursodeoxycholic acid therapy is associated with reduced risk of biliary pain and acute cholecystitis in patients with gallbladder stones: a cohort analysis.
    Tomida S; Abei M; Yamaguchi T; Matsuzaki Y; Shoda J; Tanaka N; Osuga T
    Hepatology; 1999 Jul; 30(1):6-13. PubMed ID: 10385632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ursodeoxycholic acid reduces lipid peroxidation and mucin secretagogue activity in gallbladder bile of patients with cholesterol gallstones.
    Jüngst C; Sreejayan N; Zündt B; Müller I; Spelsberg FW; Hüttl TP; Kullak-Ublick GA; del Pozo R; Jüngst D; von Ritter C
    Eur J Clin Invest; 2008 Sep; 38(9):634-9. PubMed ID: 18837739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ursodeoxycholic acid exerts no beneficial effect in patients with symptomatic gallstones awaiting cholecystectomy.
    Venneman NG; Besselink MG; Keulemans YC; Vanberge-Henegouwen GP; Boermeester MA; Broeders IA; Go PM; van Erpecum KJ
    Hepatology; 2006 Jun; 43(6):1276-83. PubMed ID: 16729326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of gallstones and their complications.
    Ahmed A; Cheung RC; Keeffe EB
    Am Fam Physician; 2000 Mar; 61(6):1673-80, 1687-8. PubMed ID: 10750875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gallbladder management in obesity surgery.
    Mason EE; Renquist KE
    Obes Surg; 2002 Apr; 12(2):222-9. PubMed ID: 11975217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trial.
    Haal S; Guman MSS; Boerlage TCC; Acherman YIZ; de Brauw LM; Bruin S; de Castro SMM; van Hooft JE; van de Laar AWJM; Moes DE; Schouten M; Schouten R; van Soest EJ; van Veen RN; de Vries CEE; Fockens P; Dijkgraaf MGW; Gerdes VEA; Voermans RP
    Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):993-1001. PubMed ID: 34715031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of gallstones by ursodeoxycholic acid after cardiac surgery.
    Ai T; Azemoto R; Saisho H
    J Gastroenterol; 2003; 38(11):1071-6. PubMed ID: 14673725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Gallstones following considerable weight loss and recommendations for their prevention].
    Mijnhout GS; Smulders YM; Craanen ME
    Ned Tijdschr Geneeskd; 2004 Jan; 148(4):174-7. PubMed ID: 14974308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gallstone formation prophylaxis after gastric restrictive procedures for weight loss: a randomized double-blind placebo-controlled trial.
    Miller K; Hell E; Lang B; Lengauer E
    Ann Surg; 2003 Nov; 238(5):697-702. PubMed ID: 14578732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gallstone disease: Microlithiasis and sludge.
    Jüngst C; Kullak-Ublick GA; Jüngst D
    Best Pract Res Clin Gastroenterol; 2006; 20(6):1053-62. PubMed ID: 17127187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gallstone size and risk of pancreatitis.
    Diehl AK; Holleman DR; Chapman JB; Schwesinger WH; Kurtin WE
    Arch Intern Med; 1997 Aug 11-25; 157(15):1674-8. PubMed ID: 9250228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Significance of biliary dysfunction in the pathogenesis of gallstone disease].
    Il'chenko IA; Deliukina OV
    Eksp Klin Gastroenterol; 2011; (7):70-8. PubMed ID: 22364003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients developed symptomatic gallstones between 3 and 21 months after Roux-en-Y gastric bypass (RYGB), neither prophylactic cholecystectomy nor treatment with ursodeoxycholic acid is necessary after open RYGB.
    Sarr MG
    Surg Obes Relat Dis; 2006; 2(2):233; author reply 233. PubMed ID: 16925352
    [No Abstract]   [Full Text] [Related]  

  • 19. Prevention of gallstone formation in morbidly obese patients undergoing rapid weight loss: results of a randomized controlled pilot study.
    Wudel LJ; Wright JK; Debelak JP; Allos TM; Shyr Y; Chapman WC
    J Surg Res; 2002 Jan; 102(1):50-6. PubMed ID: 11792152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-3 polyunsaturated fatty acid attenuates cholesterol gallstones by suppressing mucin production with a high cholesterol diet in mice.
    Kim JK; Cho SM; Kang SH; Kim E; Yi H; Yun ES; Lee DG; Cho HJ; Paik YH; Choi YK; Haam SJ; Shin HC; Lee DK
    J Gastroenterol Hepatol; 2012 Nov; 27(11):1745-51. PubMed ID: 22849613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.